Menlo Ventures said Greg Yap has joined the firm as a partner to lead investments in life science companies.
Yap was most recently an entrepreneur in residence at Illumina Ventures, where he focused on genomics investments, and he was a co-founder of PyrAmes, a digital-health company. He previously was a co-founder of Biodesy, a protein-analysis company.
Applications such as personalized medicine, genomics, synthetic biology and digital health represent huge market opportunities, he said in a press release.
Menlo plans to invest 15 percent of its $450 million Menlo XIV, or about $68 million, in early-stage companies targeting healthcare.
Advances in machine learning, AI, and big data analysis are enabling new business models and markets, and have the potential to impact human health, said Menlo Managing Director Mark Siegel. The firm believes a multidisciplinary approach is crucial, Siegel said.
Recent investments include Synthego, Cofactor Genomics, Clear Labs, Recursion Pharmaceuticals and 3T Biosciences.
Along with early-stage fund, the firm is presently investing out of its growth-focused $250 million Menlo Special Opportunity Fund.
Photo of Greg Yap, a partner at Menlo Ventures, courtesy of the firm